RESEARCH LETTER: Do Physicians Discuss Political Issues with Their Patients?
To the Editor: Politicians have an important influence on the structure and function of our health care system. As a result, it seems likely that physicians and their patients might discuss political issues of consequence to health care. Yet, little is known about physicians' attitudes and activities in this regard or about their level of personal political participation. [1] [2] [3] [4] We conducted a survey to examine the political attitudes and activities of physicians and to identify characteristics associated In conclusion, the majority of our study PCPs discussed voting or health care politics with their patients. To our knowledge, this is the first study to demonstrate that the personal political activities of physicians are associated with their willingness to address political issues with clinic patients. Moreover, we found that gender was associated with political activity inside and outside the clinic, a finding consistent with a study of English PCPs. 5 Our study was limited by the small sample size, the single health care system source of our cohort, unadjusted analyses, and self-report. Future studies should continue to explore the political attitudes and activities of physicians in different populations and settings, in addition to addressing the influence of such activities on the patients they serve. Moreover, we believe that a debate on the ethical issues surrounding political discourse in the practice setting is warranted. 
Mortality Associated with Hormone Replacement Therapy in Younger and
Older Women
In Reply:-I appreciate the opportunity to respond to Dr. Grant's letter concerning our meta-analysis on mortality associated with hormone replacement. It is true that no single trial of younger women has shown a significant reduction in mortality with hormone use. In fact, no trial of hormone replacement has shown a decrease or increase in mortality. Death is a very rare event, especially in younger postmenopausal women, and it would require a very large trial to provide the statistical power necessary to produce significant results. A more precise estimate can be made by pooling the results of many smaller trials in the form of a meta-analysis.
In the analysis of younger women, approximately one half of the deaths were from one trial with ovarian cancer survivors that provided 40% of the weight. However, as described in the article, when this trial was excluded from the analysis there still was a significant reduction in mortality for the younger age group, with an odds ratio of 0.56 (confidence interval [CI], 0.31 to 0.99). Since our analysis was published, the Women's Health Initiative estrogen-only trial has shown a hazard ratio for total mortality of 0.73 (CI, 0.47 to 1.13) in those 50 to 59 years old. 1 If these data were added to our meta-analysis, it would provide 50% of the weight, with a revised odds ratio for mortality in the younger age group of 0.67 (CI, 0.49 to 0.92). It is not possible to completely control for previous exposure to hormone replacement in clinical trials, but randomized trials help to reduce baseline differences between the treatment and control groups. In this meta-analysis, the women in the younger age group had a mean age of 53.7 years and had no recent exposure to hormone replacement, which indicates that their previous exposure to hormone replacement was probably minimal. Longer trials of hormone replacement will be needed in the future to assess whether this mortality benefit seen in younger women persists over the years.-Shelley Salpeter, MD, FACP, Santa Clara Valley Medical Center, San Jose, CA.
